# A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

> **NCT07481357** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 51 (estimated)

## Conditions studied

- Gastric (Stomach) Cancer
- GastroEsophageal Cancer
- Pancreatic Ductal Adenocarcinoma (mPDAC)

## Interventions

- **DRUG:** DA-3501

## Key facts

- **NCT ID:** NCT07481357
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2028-02
- **Final completion:** 2029-02
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07481357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07481357, "A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07481357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*